Coronary Artery Disease Pipeline Review 2021

Report Code: PMI461421 | Publish Date: February 2021 | No. of Pages: 132

Coronary Artery Disease Pipeline Review 2021 Overview

Coronary Artery Disease- Pipeline Review

It is estimated that 17.9 million people die of heart disease worldwide (also known as coronary artery disease) annually, accounting for around one third of all global deaths. Heart diseases is a leading cause of death, affecting more men than women.

Heart disease or Coronary artery disease (CAD) is chronic disease in which arteries that supply blood to heart muscle are hardened and narrowed. This is mainly attributed due to accumulation of cholesterol and other material, called plaque, on their inner walls. This accumulation of material is called atherosclerosis. As this accumulation grow, there will be less blood flow through the arteries. As a result, there will be inadequate blood or oxygen supply to the heart muscle. This can cause chest pain (angina) or a heart attack. Most heart attacks occurs when blood supply to the heart is suddenly cut off, causing permanent heart damage.

Pharmaceutical companies are focusing on launching drugs to treat Coronary artery disease. On September 2019, AstraZeneca declared in-depth results from the positive Phase III THEMIS trial. It showed that Brilinta (ticagrelor) plus aspirin decreased the relative risk for the composite of cardiovascular (CV) death, heart attack, or stroke by 10% compared with aspirin alone, a statistically significant reduction. The overall THEMIS trial population was patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack or stroke.

Approximately 70% of pipeline drugs for Coronary Artery Disease are in phase 4 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Coronary Artery Disease.


Report Description

The report on Coronary Artery Disease- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Coronary Artery Disease. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

  • Assessment of pipeline products based on various stages of devolvement.
  • Provides an overview of the global therapeutic landscape of Coronary Artery Disease (Infectious Disease).
  • Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
  • The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
  • Latest news, articles, press-release, and related conferences

Coronary Artery Disease Pipeline Review 2021 Key Issues Addressed

  • Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
  • Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
  • Build strategic initiatives by understanding the focus areas of leading companies
  • Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Coronary Artery Disease Pipeline Review 2021 Table of Contents


  1. Introduction
  • Objectives of the Study
  • Definition
  • Report Overview
  • Coronary Artery Disease Overview
  1. Executive Summary
  2. Coronary Artery Disease: Pipeline Assessment
  • Company Overview
  • Product Description
  • Status
  • Phase
  • Study Design
  • Route of Administration
  • Indication       
  • Condition        
  • NCT Number              
  • Sponsor          
  • Collaborator   
  • Brief Title         
  • Study Start Date         
  • Study completion (Estimated/Actual)
  • Study Completion Date
  • Enrollment     
  • Research Location (Listed Location Countries)
  1. Coronary Artery Disease: Analysis on Dormant & Discontinued Pipeline Candidates
  • Overview
  • Product Description
  • Reason for Discontinuation
  1. Coronary Artery Disease: Additional Key Insights
  • Epidemiology Overview: Coronary Artery Disease
  1. Coronary Artery Disease: Press Releases, Latest News and Conference Details


  • Table of Content is tentative and subject to change as the research progresses
  • The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.